New combo targets tough endometrial cancer in small trial
Disease control
Recruiting now
This phase 2 study tests whether combining avelumab (an immunotherapy) with M1774 (a targeted drug) can shrink tumors or delay cancer growth in 25 people with ARID1A-mutated endometrial cancer that has returned after prior immunotherapy. Participants receive both drugs intravenou…
Phase: PHASE2 • Sponsor: Panagiotis Konstantinopoulos, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC